Genetic evolution of rotavirus G-types circulating in Palermo, Italy, over the last fifteen years

Epidemiologia delle infezioni da Rotavirus di gruppo A a Palermo: evoluzione genetica dei ceppi circolanti isolati dal 1991 al 2004

Variability of G2 Rotavirus strains infecting the infantile population in Palermo, Italy, over a period of 12 years (1993-2004).

Heterogeneity and temporal dynamics of evolution of G1 human rotaviruses in a settled population.

ABSTRACT A rotavirus sample collection from 19 consecutive years was used to investigate the heterogeneity and the dynamics of evolution of G1 rotavirus strains in a geographically defined population. Phylogenetic analysis of the VP7 gene sequences of G1P[8] human rotavirus strains showed the circulation of a heterogeneous population comprising three lineages and seven sublineages. Increases in the circulation of G1 rotaviruses were apparently associated with the introduction of novel G1 strains that exhibited multiple amino acid changes in antigenic regions involved in rotavirus neutralization compared to the strains circulating in the previous years. The emergence and/or introduction of G…

Pre-empitive treatment with ciclofovir for cytomegalovirus antigenemia in autologous bone marrow recipient and CLL patients on therapy with alentuzumab

Pre-Emptive Treatment with Cidofovir for Cytomegalovirus Antigenemia in Autologous Bone Marrow Recipient and CLL Patients on Therapy with Alemtuzumab.

Abstract Cytomegalovirus (CMV) is an important cause of morbidity and mortality in patients who have undergone severe immunosuppressive therapy. Ganciclovir continues to be the first choice for pre-emptive therapy, but it needs multiple intravenous daily administration for three weeks and may cause myelosuppression. Cidofovir is a non myelotoxic nucleotide analogue effective against CMV; its favourable pharmacokinetic profile allows a once-a-week dosing. We reviewed a database on 110 consecutive Autologous Stem Cell Transplant (ASCT) and that of 15 Chronic Lymphocytic Leukemia (CLL) patients treated with alemtuzumab. All patients were virologically monitored by quantification of pp65 antige…